title: Clinical course, prognostic factors, and long-term outcomes of malignant middle cerebral artery infarction patients in the modern era.
abstract: BACKGROUND
  Recanalization therapies have been increasingly applied in clinical practice, which might change the outcomes of patients with large middle cerebral artery (MCA) infarction. The purpose of this study was to study the clinical course, prognostic factors, and long-term outcomes of patients with an acute large MCA infarction.
  
  
  METHODS
  Patients with an acute large MCA infarction who were treated between January, 2011 - March, 2014 were studied. The demographics and vascular risk factors were compared between patients with and without clinical outcomes of interest, favorable outcome and death.
  
  
  RESULTS
  From a total of 1538 patients, 200 patients with large MCA infarction were included. The mean age was 67 years. The mean National Institute of Health Stroke Scale score was 20. The mean time from onset to the hospital was 289 min. Intravenous recombinant-tissue-plasminogen activator (rtPA) was given in 50 patients (25%). The mean follow-up time was 13 months. 51 patients (51/191, 27%) had a favorable outcome (modified Rankin Scale 0-2) at the final follow-up. 81 patients (81/191, 42%) died. A younger age, less severe stroke, rtPA treatment, and large-artery atherosclerosis stroke subtype were related to a favorable outcome. Older age and presence of coronary artery disease were associated with death and rtPA treatment was inversely related to death.
  
  
  CONCLUSIONS
  Prognosis of patients with a large MCA infarction is still poor. Favorable outcomes were found in only a fourth of the total patients, and a high mortality rate was still present. Intravenous rtPA treatment seemed to be related to a favorable outcome.
authors.affiliation: Department of Internal Medicine, Stroke and Neurodegenerative Diseases Research Unit, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
authors.forename: Pornpatr A
authors.initials: PA
authors.lastname: Dharmasaroja
authors.forename: Sombat
authors.initials: S
authors.lastname: Muengtaweepongsa
authors.forename: Junya
authors.initials: J
authors.lastname: Pattaraarchachai
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology / Q000628:therapy*; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010959:Tissue Plasminogen Activator